News and insights

Strengthening India’s Pharmaceutical and Medical Device Manufacturing

Gloved hands handling capsules in a laboratory environment.
Photo by Pilan Filmes via Pexels. Free Pexels image: https://www.pexels.com/photo/work-in-a-lab-11589208/

Published: November 9, 2026

The Government of India’s Production Linked Incentive (PLI) schemes are intended to encourage domestic investment and manufacturing capacity in selected parts of the pharmaceutical and medical device sectors. A Department of Pharmaceuticals release carried by the Press Information Bureau describes three schemes covering bulk drugs, pharmaceuticals and medical devices.

Different schemes address different supply needs

The bulk-drugs scheme focuses on domestic production of identified key starting materials, drug intermediates and active pharmaceutical ingredients. The pharmaceutical PLI scheme supports eligible manufacturing across areas that include higher-value medicines and specified ingredients. A separate medical-device scheme is aimed at eligible devices and segments where domestic capacity is being encouraged.

How incentives are structured

According to the PIB release, the schemes use financial incentives linked to defined eligibility, investment, production or sales conditions. The government reports scheme-level figures for approved projects, investment and production as of June 2026. These are government-reported outcomes and should not be read as a benefit available to every company.

For the wider supply chain, domestic capacity may create opportunities for qualified suppliers and business partners. Participation remains subject to scheme rules, licensing, product requirements and the relevant company’s eligibility.

Source: Press Information Bureau, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, release published September 25, 2026. Read Original Source.